ATE319817T1 - Gegen inaktivierung resistenter faktor viii - Google Patents
Gegen inaktivierung resistenter faktor viiiInfo
- Publication number
- ATE319817T1 ATE319817T1 AT97927596T AT97927596T ATE319817T1 AT E319817 T1 ATE319817 T1 AT E319817T1 AT 97927596 T AT97927596 T AT 97927596T AT 97927596 T AT97927596 T AT 97927596T AT E319817 T1 ATE319817 T1 AT E319817T1
- Authority
- AT
- Austria
- Prior art keywords
- acid sequences
- sequences
- proteins
- amino acid
- nucleic acid
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical group 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000057593 human F8 Human genes 0.000 abstract 3
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1611796P | 1996-04-24 | 1996-04-24 | |
US1778596P | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE319817T1 true ATE319817T1 (de) | 2006-03-15 |
Family
ID=26688196
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06004484T ATE502958T1 (de) | 1996-04-24 | 1997-04-24 | Gegen inaktivierung resistenter faktor viii |
AT97927596T ATE319817T1 (de) | 1996-04-24 | 1997-04-24 | Gegen inaktivierung resistenter faktor viii |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06004484T ATE502958T1 (de) | 1996-04-24 | 1997-04-24 | Gegen inaktivierung resistenter faktor viii |
Country Status (10)
Country | Link |
---|---|
US (2) | US6838437B2 (de) |
EP (3) | EP1754718B1 (de) |
JP (2) | JP3987114B2 (de) |
AT (2) | ATE502958T1 (de) |
AU (1) | AU3202797A (de) |
CA (1) | CA2252896C (de) |
DE (2) | DE69735421T2 (de) |
DK (1) | DK1754718T3 (de) |
PT (1) | PT1754718E (de) |
WO (1) | WO1997040145A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69615185T2 (de) * | 1995-06-12 | 2002-06-13 | Sanquin Bloedvoorziening | Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung |
CA2252896C (en) | 1996-04-24 | 2009-03-10 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
AU3289599A (en) * | 1998-02-13 | 1999-08-30 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
US7615622B2 (en) * | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
US7211558B2 (en) * | 2002-05-22 | 2007-05-01 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia A |
US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
EP1502921A1 (de) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Rekombinanter mutierter menschlicher Factor VIII (FVIII) mit verbesserter Stabilität |
ES2395544T3 (es) * | 2004-12-23 | 2013-02-13 | Novo Nordisk Health Care Ag | Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés |
US20110124565A1 (en) * | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
US20080070251A1 (en) * | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
EP3231440A1 (de) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Veränderte koagulationsfaktoren mit verlängerter in-vivo-halbwertzeit |
WO2009156137A1 (en) | 2008-06-24 | 2009-12-30 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
AU2011323236B2 (en) * | 2010-11-05 | 2017-03-30 | Takeda Pharmaceutical Company Limited | A new variant of antihemophilic factor VIII having increased specific activity |
SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
ES2595160T3 (es) | 2011-10-18 | 2016-12-28 | Csl Behring Gmbh | Uso combinado de un glucosaminoglicano sulfatado y una hialuronidasa para mejorar la biodisponibilidad del Factor VIII |
CN103889445A (zh) | 2011-10-18 | 2014-06-25 | 德国杰特贝林生物制品有限公司 | 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途 |
EP2768853A1 (de) | 2011-10-18 | 2014-08-27 | CSL Limited | Verfahren zur verbesserung der stabilität von gereinigtem faktor viii nach der rekonstitution |
DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
US20150337028A1 (en) * | 2012-09-12 | 2015-11-26 | Centre For Bioseparation Technology-Vit | Double Mutant Coagulation Factor VIII and Methods Thereof |
RU2015125343A (ru) | 2012-11-29 | 2017-01-11 | БАЙЕР ХелсКер ЛЛСи | Гуманизированные моноклональные антитела против активированного белка с и их применение |
AU2013352159A1 (en) * | 2012-11-29 | 2015-06-04 | Bayer Healthcare Llc | Monoclonal antibodies agaisnt activated Protein C (aPC) |
CA2906602A1 (en) | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Variant factor viii polypeptides and methods of their production and use |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
EP3114138B1 (de) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Verbesserte muteine von gerinnungsfaktor viii |
US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
SG11201706657PA (en) * | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
BR112017023785A2 (pt) | 2015-05-22 | 2018-07-17 | Csl Behring Recombinant Facility Ag | polipeptídeos do fator de von willebrand truncados para tratar hemofilia |
CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
CA3010720A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
KR20190073576A (ko) | 2016-11-11 | 2019-06-26 | 체에스엘 베링 렝나우 아게 | 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
CA3043250A1 (en) | 2016-11-11 | 2018-05-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
JP2022512787A (ja) * | 2018-10-23 | 2022-02-07 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 第viii因子機能を調節するための組成物および方法 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
EP4069269A4 (de) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | Zusammensetzungen und verfahren zur modulation der faktor-viii-funktion |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214033A (en) | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US5045455A (en) | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
EP0253870B1 (de) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Verfahren zur herstellung von faktor-viii:c-typ-proteinen |
AT388079B (de) | 1986-04-18 | 1989-04-25 | Helmut Ing Koenig | Backofen |
US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
EP0500734B1 (de) | 1989-11-17 | 1998-02-11 | Novo Nordisk A/S | Proteinkomplexe mit faktor viii:c-aktivität und deren herstellung |
US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
AU6456096A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
CA2252896C (en) | 1996-04-24 | 2009-03-10 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
-
1997
- 1997-04-24 CA CA002252896A patent/CA2252896C/en not_active Expired - Fee Related
- 1997-04-24 JP JP53821697A patent/JP3987114B2/ja not_active Expired - Fee Related
- 1997-04-24 AU AU32027/97A patent/AU3202797A/en not_active Abandoned
- 1997-04-24 DE DE69735421T patent/DE69735421T2/de not_active Expired - Lifetime
- 1997-04-24 WO PCT/US1997/006563 patent/WO1997040145A1/en active IP Right Grant
- 1997-04-24 EP EP06004484A patent/EP1754718B1/de not_active Expired - Lifetime
- 1997-04-24 PT PT06004484T patent/PT1754718E/pt unknown
- 1997-04-24 EP EP97927596A patent/EP0910628B1/de not_active Expired - Lifetime
- 1997-04-24 EP EP10157809A patent/EP2202242A1/de not_active Withdrawn
- 1997-04-24 AT AT06004484T patent/ATE502958T1/de active
- 1997-04-24 DE DE69740154T patent/DE69740154D1/de not_active Expired - Lifetime
- 1997-04-24 DK DK06004484.9T patent/DK1754718T3/da active
- 1997-04-24 AT AT97927596T patent/ATE319817T1/de not_active IP Right Cessation
-
2001
- 2001-04-11 US US09/819,098 patent/US6838437B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/974,534 patent/US7459534B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 JP JP2007101700A patent/JP4250661B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4250661B2 (ja) | 2009-04-08 |
EP2202242A1 (de) | 2010-06-30 |
EP0910628B1 (de) | 2006-03-08 |
JP2007228973A (ja) | 2007-09-13 |
US20060014683A1 (en) | 2006-01-19 |
US6838437B2 (en) | 2005-01-04 |
PT1754718E (pt) | 2011-07-13 |
US7459534B2 (en) | 2008-12-02 |
US20020132306A1 (en) | 2002-09-19 |
WO1997040145A1 (en) | 1997-10-30 |
AU3202797A (en) | 1997-11-12 |
CA2252896C (en) | 2009-03-10 |
DK1754718T3 (da) | 2011-07-18 |
DE69740154D1 (de) | 2011-05-05 |
CA2252896A1 (en) | 1997-10-30 |
JP2000511407A (ja) | 2000-09-05 |
EP1754718A3 (de) | 2007-05-16 |
DE69735421T2 (de) | 2006-10-19 |
JP3987114B2 (ja) | 2007-10-03 |
EP0910628A4 (de) | 2001-05-02 |
EP1754718A2 (de) | 2007-02-21 |
ATE502958T1 (de) | 2011-04-15 |
EP1754718B1 (de) | 2011-03-23 |
DE69735421D1 (de) | 2006-05-04 |
EP0910628A1 (de) | 1999-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE502958T1 (de) | Gegen inaktivierung resistenter faktor viii | |
DK0672138T3 (da) | Kimære prokoagulante proteiner | |
DE69018920D1 (de) | Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine. | |
GEP20033002B (en) | Osteoprotegerin Binding Protein and Receptors | |
RU95115239A (ru) | Аналог эритропоэтина | |
DE3854952D1 (de) | Mykobakterielle rekombinanten und peptide | |
DE3587875D1 (de) | Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu. | |
ATE286974T1 (de) | Therapeutische domänen des von willebrand-faktor | |
ATE211390T1 (de) | Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung | |
DE59712235D1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
SE9602822D0 (sv) | New receptor | |
ATE190630T1 (de) | Angiotensin-ii typ-1 rezeptor und dessen herstellung | |
DE69027967D1 (de) | Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen | |
WO1990003394A3 (fr) | Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines | |
DE60124380D1 (de) | Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure | |
FI921356A (fi) | Somatostatinreceptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |